Navigation Links
Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results
Date:2/27/2012

MISSISSAUGA, Ontario, Feb. 27, 2012 /PRNewswire/ --

Fourth Quarter 2011

  • 2011 Fourth Quarter Total Revenue $688.5 million; an increase of 34% over the prior year
  • Pro forma organic growth, excluding the impact of foreign exchange and acquisitions, was 10%
  • 2011 Fourth Quarter GAAP EPS $0.18; Cash EPS $0.94
  • 2011 Fourth Quarter GAAP Operating Cash Flow $190 million; Adjusted Operating Cash Flow $253 million  

  • Full Year 2011

  • Total 2011 revenue was $2.46 billion
  • Total 2011 pro forma organic growth, excluding the impact of foreign exchange and acquisitions, was 9%
  • Total 2011 GAAP EPS $0.49; Cash EPS $2.93
  • Total 2011 GAAP Operating Cash Flow $676 million; Adjusted Operating Cash Flow $925 million

  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces fourth quarter financial results for 2011.

    "We are pleased by our financial results for the fourth quarter and the full year," said J. Michael Pearson, chairman and chief executive officer. "Our performance continues to demonstrate the strength of our diversified model and our capacity to integrate acquisitions and still deliver strong top-line and bottom-line results."

    RevenueTotal reported revenue was $688.4 million in the fourth quarter of 2011 as compared to $514.6 million in the fourth quarter of 2010 primarily attributable to acquisitions completed in 2011 and the growth of key dermatology brands, partly offset by a negative foreign exchange impact.  

    Product sales were $654.2 million in the fourth quarter of 2011, as compared to $488.7 million in the 2010 year quarter.  Pro forma organic growth for the Company was 10% for the fourth quarter of 2011 and 9% for the full year 2011.

    Operating ExpensesThe Compa
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Valeant to Acquire Polish Products
    2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
    3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
    4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
    5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
    6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
    7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
    8. Valeant Announces Pricing of Senior Notes
    9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
    10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
    11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... This test can detect HIV infection if used ... by activities that can transfer body fluids from one person ... shared needles. , An in-vitro diagnostic home-use test ... test works by looking for your body,s response to fighting ... enabling patients to learn their status in a single visit ...
    (Date:9/23/2014)... Research and Markets has announced the addition ... report to their offering. Though biotechnology ... products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders ... stages of clinical drug testing for new biopharmaceuticals, as ... to upscale while anticipating FDA or EMA approval. During ...
    (Date:9/23/2014)... FRANCISCO , Sept. 23, 2014  SiteOne Therapeutics ... of equity financing. Led by Sears Capital Management and ... Joe Zakrzewski , the $1.5 million financing positions ... program for pain and to further develop its technology ... pain indications. In conjunction with the financing, ...
    Breaking Medicine Technology:WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
    ... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
    ... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
    Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
    (Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
    (Date:9/23/2014)... Davis, and Academia Sinica, the preeminent academic institution ... into a collaborative agreement to develop a unique ... research with opportunities to translate innovative technologies and ... agreement was signed Sept.12 in Taipei by Harris ... and President Chi-Huey Wong of Academia Sinica. The ...
    (Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
    (Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
    (Date:9/23/2014)... 2014 (HealthDay News) -- Both drinking and getting drunk ... alcohol abuse by high school students, a new study ... high school students who drink, could help expand alcohol-prevention ... drink, to stop them from becoming binge drinkers, the ... of first alcohol use and progression to first heavy ...
    Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3
    ... Reactors Could Solve the Isotope Crisis within 24 months ... Nordion, a leading provider of medical isotopes and radiopharmaceuticals, ... Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) ... to the shortage of medical radioisotopes is the completion ...
    ... male and seven female) with hepatic angiomyolipoma, with a ... Of these patients, dynamic contrast CT showed hepatic angiomyolipoma ... of a capsule, and prominent central vessels in six ... without a fat component in four cases with tuberous ...
    ... , DENVER July 30 Air Methods Corporation ... quarter ended June 30, 2009 after the close of the market on ... for Thursday, August 6, 2009 at 4:15 p.m. Eastern to discuss these ... the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or ...
    ... , PLEASANTON, Calif., July 30 TriReme ... second product, a novel coronary dilatation catheter, designed to improve ... near side branches. The product will be marketed under the ... a first-in-class balloon dilatation catheter with a torquable shaft and ...
    ... centers didn,t increase weight, study found , THURSDAY, July 30 ... else,s home, they,re more likely to be heavier than average ... researchers report in the August issue of Pediatrics ... for in someone else,s home, rather than in their own ...
    ... WILMINGTON, Del., July 30 AstraZeneca (NYSE: ... a New Drug Application to the U.S. Food and Drug ... European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 ... of advanced non-small cell lung cancer in patients previously treated ...
    Cached Medicine News:Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 2Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 3Health News:TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 2Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 4
    ... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
    RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
    ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
    ... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
    Medicine Products: